TY - JOUR
T1 - Identification of two new translocations that disrupt the AML1 gene
AU - Richkind, Kathleen
AU - Hromas, Robert
AU - Lytle, C.
AU - Crenshaw, D.
AU - Velasco, J.
AU - Roherty, S.
AU - Srinivasiah, Jayanthi
AU - Varella-Garcia, Marileila
N1 - Funding Information:
RH is supported by NIH RO1 HL48914, PO1 CA74295, and a Translational Research Award from the Leukemia Society of America.
PY - 2000/10/15
Y1 - 2000/10/15
N2 - The AML1 gene, located at chromosome 21q22, encodes a component (CBFα2) of a heterodimeric transcription factor complex termed core binding factor (CBF), which binds to DNA and activates gene expression. Chromosomal rearrangements may lead to disruption of this gene and development of acute leukemia. Twelve AML1 translocations have been identified to date, and include sites on chromosomes 1, 2, 3, 5, 8, 12, 14, 15, 16, 17, 18, and 19. Here we report two new translocations involving AML1 in acute myeloid leukemia, in which the disruption of the AML1 gene was documented by GTG banding cytogenetic studies and metaphase and interphase FISH analysis. These chromosomal breakpoints identified as harboring new fusion partners for AML1 are at 2p11.2 and 20q13.1. The two patients in who these translocation were identified were elderly males with newly diagnosed AML. These patients shared the same poor outcomes reported for other rare AML1 translocations. (C) 2000 Elsevier Scinece Inc.
AB - The AML1 gene, located at chromosome 21q22, encodes a component (CBFα2) of a heterodimeric transcription factor complex termed core binding factor (CBF), which binds to DNA and activates gene expression. Chromosomal rearrangements may lead to disruption of this gene and development of acute leukemia. Twelve AML1 translocations have been identified to date, and include sites on chromosomes 1, 2, 3, 5, 8, 12, 14, 15, 16, 17, 18, and 19. Here we report two new translocations involving AML1 in acute myeloid leukemia, in which the disruption of the AML1 gene was documented by GTG banding cytogenetic studies and metaphase and interphase FISH analysis. These chromosomal breakpoints identified as harboring new fusion partners for AML1 are at 2p11.2 and 20q13.1. The two patients in who these translocation were identified were elderly males with newly diagnosed AML. These patients shared the same poor outcomes reported for other rare AML1 translocations. (C) 2000 Elsevier Scinece Inc.
UR - http://www.scopus.com/inward/record.url?scp=0034667259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034667259&partnerID=8YFLogxK
U2 - 10.1016/S0165-4608(00)00284-3
DO - 10.1016/S0165-4608(00)00284-3
M3 - Article
C2 - 11106827
AN - SCOPUS:0034667259
SN - 0165-4608
VL - 122
SP - 141
EP - 143
JO - Cancer Genetics and Cytogenetics
JF - Cancer Genetics and Cytogenetics
IS - 2
ER -